

FULL PUBLICATIONS:

Garbe E, Suling M, Kloss S, Lindemann C, Schmid U. Linkage of mother-baby pairs in the German Pharmacoepidemiological Research Database. Pharmacoepidemiol Drug Saf (in press)

Behr S, Andersohn F, **Garbe E**. Risk of intracerebral hemorrhage associated with phenprocoumon exposure: a nested case-control study in a large population-based German database. Pharmacoepidemiol Drug Saf 2010; 19: 722-30

Andersohn F, Schade R, Willich SN, **Garbe E**. Use of antiepileptic drugs in epilepsy and the risk of self harm or suicidal behaviour. Neurology 2010;75: 335-40.

Renoux C, Dell'Aniello S, **Garbe E**, Suissa S. Transdermal versus oral hormone replacement therapy and the risk of stroke: nested case-control study. BMJ 2010; 340: c2519

Andersohn F, Waring M, **Garbe E**. Risk of ischemic stroke in patients with Crohn's disease: A population based nested case-control study. Inflammatory Bowel Diseases 2010; 16:1387-92

Andersohn F, Schmedt N, Weinmann S, Willich SN, **Garbe E**. Priapism Associated with Antipsychotics: Role of Alpha-1 Adrenoceptor Affinity. J Clin Psychopharmacol 2010, 30; 68-71

Cox E, Martin BC, Van Staa T, **Garbe E**, Siebert U, Johnson ML. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of non-randomized studies of treatment effects using secondary data sources. Report of the ISPOR Retrospective Database Analysis Task Force – Part II. Value in Health 2009; Sept. 10 (epub ahead of print)

Andersohn F, Konzen C, Bronder E, Klimpel A, **Garbe E**. Citalopram induced bleeding due to profound thrombocytopenia. Psychosomatics 2009; 50: 297-298

Spitler LE, Weber RW, Allen RE, Meyer J, Cruickshank S, **Garbe E**, Lin HY, Soong SJ. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, Sargramostim) administered for three years as adjuvant therapy of stage II(T4), III, and IV melanoma. J Immunother 2009, 32: 632-637

Andersohn F, Schade R, Suissa S, **Garbe E**. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009; 166: 591-8

Blaschke D, Rolf S, Parwani AS, Huemer M, Dietz R, **Garbe E**, Haverkamp W. Pharmaka-induzierte Herzklappenveränderungen. Dtsch Med Wochenschr 2009; 134: 365-370

Sehouli J, Mahner S, **Garbe E**, Oskay-Özcelik G. Die ältere Patientin in der Gynäkologischen Onkologie. Praktische Fortbildung Gynäkologie, Geburtsmedizin und Gynäkologische Endokrinologie 2008; 4: 264-276

Eisele S, **Garbe E**, Zeitz M, Schneider T, Somasundaram R. Ciprofloxacin-related acute severe myalgia necessitating emergency care treatment: a case report and review of the literature. International Journal of Clinical Pharmacology and Therapeutics 2009; 47: 165-168.

Andersohn F, **Garbe E**. Cardiac and noncardiac fibrotic reactions caused by ergot- and nonergot-derived dopamine agonists. Movement Disorders 2009; 24:129-33. (IF 4.014)

Renoux C, Dell’Aniello S, **Garbe E**, Suissa S. Hormone replacement therapy use and the risk of stroke. Maturitas 2008; 61: 305-309

Hoffmann F, Andersohn F, Giersiepen K, Scharnetzky E, **Garbe E**: Validierung von Sekundärdaten - Grenzen und Möglichkeiten (*Validation of secondary data – limitations and opportunities*). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2008; 51:1118-26

Andersohn F, **Garbe E**. Pharmakoepidemiologische Forschung mit Routinedaten des Gesundheitswesens (*Pharmacoepidemiological research with routine healthcare data*). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2008; 51: 1135-44.

Suissa S, **Garbe E**. Primer: administrative health databases in observational studies of drug effects - advantages and disadvantages. Nat Clin Pract Rheumatol 2007; 12:725-32.

Garbe E. Non-chemotherapy drug-induced agranulocytosis. Exp Opin Drug Saf 2007; 6: 323-335

Andersohn F, Konzen C, **Garbe E**. Systematic review: Agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 2007; 146: 657-665

Schade R, Andersohn F, Suissa S, Haverkamp W, **Garbe E**. Dopamine agonists and the risk of cardiac valve regurgitation. N Engl J Med 2007; 356: 29-38

Garbe E, Andersohn F. Contraindication labelling changes in the United States and Germany. Eur J Clin Pharmacol 2007, 63: 87-93

Andersohn F, Schade R, Suissa S, **Garbe E**. COX-2 selective NSAIDs and the risk of ischemic stroke: A nested case-control study. Stroke 2006; 37: 1725-30

Andersohn F, Suissa S, **Garbe E**. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 2006; 113: 1950-7

Heinemann LA, **Garbe E**, Lewis M, van der Woude F, Graf H. Case-control study on analgesics and nephropathy (SAN): protocol. BMC Nephrology 2005; 6: 9

Jochmann N, Stangl K, **Garbe E**, Baumann G, Stangl V. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Hear J 2005, 26: 1585-95

Andersohn F, Bronder E, Klimpel A, **Garbe E**. The proportion of drug-related serious rare blood dyscrasias: Estimates from the Berlin Case-Control Surveillance Study. American J Hematology 2004; 77: 316-8

Andersohn F, Hagmann FG, **Garbe E**. Thrombotic thrombocytopenic purpura / haemolytic uraemic syndrome associated with clopidogrel: report of two new cases. Heart 2004; 90: e57

Ahrens N, Schewior L, **Garbe E**, Kiesewetter H, Salama A. Massive haemolysis after intramuscular diclofenac in a patient who apparently tolerated oral medication. Vox Sang 2004; 86: 71-74

Garbe E, Meyer O, Andersohn F, Aslan T, Kiesewetter H, Salama A. Amlodipine-induced immune thrombocytopenia. Vox Sang 2004; 86: 75-76

Garbe E, Suissa S. Issues to debate on the Women's Health Initiative (WHI) study. Hormone replacement therapy and acute coronary outcomes: Methodological issues between randomized and observational studies. Human Reproduction 2004; 19: 8-13.

Garbe E, Levesque L, Suissa S: Variability of breast cancer risk in observational studies of hormone replacement therapy: A meta-regression analysis. Maturitas 2004; 47: 175-83

Klotz U, Beil W, Gleiter C, Drewelow B, **Garbe E**, Gillessen A, Mutschler E. [Drug interactions. Mechanisms and clinical relevance]. Internist 2003; 44: 1444-1449

Heinemann K, Moehner S, Lewis M, Assmann A, **Garbe E**, Heinemann LA. [Trends of OC use 1980-1999 in a German cohort of women]. Zentralbl Gynakol 2002 ;124:128-31

Heinemann LA, Lewis MA, Kühl-Habich D, Braendle W, **Garbe E**, Möhner S. [Lifetime history of oral contraceptive use and development of tumours of the uterus and ovary]. Geburtsh Frauenheilk 2002, 62: 566-573

Heinemann K, Möhner S, Assmann A, Lewis M, Raff T, **Garbe E**, Heinemann LA. Trend der HRT Nutzung in Deutschland 1980-1999. Ergebnisse der Deutschen Kohortenstudie zur Frauengesundheit. Frauenarzt 2002, 43: 508-511

Meisel C, **Garbe E**. [Relevance of pharmacogenomic parameters in postmarketing surveillance]. MedGen 2001, 13: 276-280

Heinemann LAJ, **Garbe E**, Farmer R, Lewis M. Venous thromboembolism and oral contraceptive use: a methodological study of diagnostic suspicion and referral bias. Eur J Contracept Reprod Health Care 2000; 5: 183-191

Garbe E, Heinemann LAJ, Rabe T, Winkler UH. [Non-contraceptive benefits of the pill--an often neglected fact]. Zentralbl Gynakol 2000, 122: 18-27

Heinemann LAJ, **Garbe E**, Winkler UH, Rabe T. [German Cohort Study of Women's Health--benefits of oral contraceptives]. Study protocol. Zentralbl Gynakol 2000, 122: 112-115

Garbe E. [Pharmacoepidemiological analysis of ocular side effects of inhaled glucocorticoids]. Klin Pharmakol akt 2000, 11: 2-5

Follmann M, Heinemann LAJ, Bauerfeind A, **Garbe E**. Treatment with potentially hepatotoxic drugs and the risk of hepatocellular carcinoma. Results of a European case-control study. Pharmacoepidemiol Drug Saf 2000; 9: 417-422

Brockmüller J, Cascorbi I, Meisel C, Kaiser R, Stangl K, **Garbe E**, Roots I. [Molecular medicine is reality]. Humboldt-Spektrum 1999, 3: 4-11

Heinemann LAJ, Assmann A, DoMinh T, **Garbe E**. Oral Progestogen-Only Contraceptives and Cardiovascular Risk: Results from Transnational Study on Oral Contraceptives and the Health of Young Women. Transnational Research Group on Oral Contraceptives and the Health of Young Women. Eur J Contracept Reprod Health Care 1999, 4: 67-73

Garbe E, Boivin J, LeLorier J, Suissa S. Selection of controls in database case-control studies: Glucocorticoids and the risk of glaucoma. J Clin Epidemiol 1998; 51: 129-135

Heinemann LAJ, **Garbe E**. Third generation oral contraceptives and the risk of venous thromboembolism. Middle East Fertility Society Journal 1998; 3: 29-34

Garbe E, LeLorier J, Suissa S. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 1998; 280: 539-543

Garbe E, Müller-Oerlinghausen B. [Foreign databases for research after drug licensing. A model also for Germany?] Deutsches Ärzteblatt 1998; 49: 3138-3143

Heinemann LAJ, **Garbe E**, Claßen E, Willich SN, Barth W, Thiel C. [Trends in cardiovascular risk factor profiles in East Germany. Three independent population studies as part of the project MONICA East Germany]. Deutsche Medizinische Wochenschrift 1998, 123: 889-895

Garbe E, LeLorier J, Suissa S. Exposure to allopurinol and the risk of cataract extraction in elderly patients. Archives of Ophthalmology 1998,116: 1652-1656

Heinemann LAJ , Barth W, **Garbe E**, Willich SN, Kunze K und die Forschungsgruppe MONICA Ostdeutschland. [Epidemiologic data of stroke. Data of the WHO-MONICA Project in Germany]. Nervenarzt 1998, 69: 1091-1099

Garbe E, LeLorier J, Boivin J, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997; 277: 722-727

Garbe E, LeLorier J, Boivin J, Suissa S. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet 1997; 350: 979-982

Heinemann LAJ, DoMinh T, Guggenmoos-Holzmann I, Thiel C, **Garbe E** (manuscript prepared for the collaborative MILTS Project Team). Oral contraceptives and liver cancer. Results of the Multicentre International Liver Tumor Study (MILTS). Contraception 1997, 56: 275-284

Garbe C, Weiss J, Krüger S, **Garbe E** et al. The German melanoma registry and environmental risk factors implied. Recent Results in Cancer Research 1993; 128: 69-89

Garbe E, Röhmel J, Gundert-Remy U. Clinical and statistical issues for therapeutic equivalence trials. Eur J Clin Pharmacol 1993; 45: 1-7

LETTERS:

Andersohn F, Suissa S, **Garbe E**. Biphasic fracture risk in diabetes: A population-based study. Bone 2008; 42: 235

Scharnetzky E, Schill W, **Garbe E**. Long-term mortality associated with aprotinin following coronary artery bypass graft surgery (letter). JAMA 2007; 297: 2475

Andersohn F, Suissa S, **Garbe E**. Cyclooxygenase inhibitors and cardiovascular risk (letter). JAMA 2007; 297: 586-7

Andersohn F, Suissa S, **Garbe E**. Risks and benefits of celecoxib to prevent colorectal adenomas (letter). N Engl J Med 2006; 355: 2371

Scharnetzky E, Andersohn F, Schill W, **Garbe E**, Pigeot I. Wie viele durch Rofecoxib Geschädigte in Deutschland (letter)? Med Klin 2006; 101; 675-676

Garbe E, Suissa S. Risks of postmenopausal hormone replacement (letter). JAMA 2002; 288: 2822.

Clark P, **Garbe E**, Habbick B, Lawrence V, Spitzer WO. Questions on breast-implants study (letter). Lancet 1998, 351: 1358-1359

Suissa S, **Garbe E**. Risk of hypoglycemia with antihypertensive medication (letter). JAMA 1997, 278: 1570

Garbe E, Suissa S. Inhaled glucocorticoids and the risk of cataracts (letter). N Engl J Med 1997; 337: 1555

BOOK CHAPTERS:

Garbe E. Nutzung von Sekundärdaten für ein Versorgungsmonitoring: zur Notwendigkeit einer Validierung. In: Kurth BM (Ed.) Monitoring der gesundheitlichen Versorgung in Deutschland. Konzepte, Anforderungen, Datenquellen. Report Versorgungsforschung. Deutscher Ärzteverlag 2008: 49-56

Garbe E. Sex-related Differences in Pharmacokinetics and Drug Effects. In: Regitz-Zagrosek V, Fuchs J (Eds): Geschlechterforschung in der Medizin. Peter Lang Verlag Frankfurt am Main 2006: 49-67

Garbe E, Suissa S. Pharmacoepidemiology. In: Ahrens W, Pigeot I (Eds): Handbook of Epidemiology. Springer Verlag Berlin 2005: 1225-1266

Hasford J, Schubert I, **Garbe E**, Dietlein G, Glaeske G. Memorandum to usefulness and necessity of pharmacoepidemiological databases in Germany (Memorandum zu Nutzen und Notwendigkeit pharmakoepidemiologischer Datenbanken in Deutschland.) Berlin – Bremen – Frankfurt – Köln – München 2004

Garbe E. Pharmacoepidemiological analysis of ocular hypertension, open-angle glaucoma and cataract as adverse effects of glucocorticoids (Pharmakoepidemiologische Analyse zu okulärer Hypertension, Offenwinkelglaukom und Katarakt als unerwünschte Wirkungen von Glukokortikoiden). Habilitation thesis Charité 2000

Heinemann LAJ, **Garbe E**. Cardiovascular Risks Associated with Oral Contraceptives. In: Rabe T, Runnebaum B (eds.). Fertility Control – Update and Trends. Springer Verlag Berlin Heidelberg 1999: 91-119

Garbe E. Malignant melanoma in the central registry of the German Dermatological Society
(Das maligne Melanom im Zentralregister der Deutschen Dermatologischen Gesellschaft).
Dissertation thesis in medicine. Free University Berlin 1991